Recurrent Ovarian Germ Cell Tumor Clinical Trial
Official title:
A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors
This phase II trial is studying alvocidib and oxaliplatin to see how well they work when given with or without fluorouracil and leucovorin calcium in treating patients with relapsed or refractory germ cell tumors. Drugs used in chemotherapy, such as alvocidib, oxaliplatin, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving alvocidib together with oxaliplatin with or without fluorouracil and leucovorin calcium may kill more tumor cells.
Status | Completed |
Enrollment | 37 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed germ cell tumor (GCT) - Seminoma or non-seminoma - Progressive disease after prior cisplatin-based therapy AND meets 1 of the following criteria: - Not considered to be a candidate for potentially curative therapy - Previously treated with high-dose chemotherapy regimens - Does not wish to undergo potentially curative high-dose therapy - Measurable or evaluable disease, as defined by 1 of the following criteria: - Unidimensionally measurable metastatic disease, defined as = 1 malignant tumor mass that can be accurately measured in = 1 dimension as = 20 mm by conventional CT scan or MRI or as = 10 mm by spiral CT scan - Bone lesions, ascites, peritoneal carcinomatosis, miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable disease - Patients with measurable disease only (i.e., normal tumor markers) must have = 1 site of disease that has not been previously irradiated - Elevation of alpha-fetoprotein > 15 ng/mL and/or elevation of beta-human chorionic gonadotropin > 2.2 mIU/L - If tumor markers are not elevated, = 1 site of measurable disease must be present - No known untreated CNS metastasis or primary CNS tumor - Patients who have undergone local treatment for brain metastases and whose brain metastases are demonstrated to be stable by repeat imaging studies performed = 4 weeks after treatment are eligible - Karnofsky performance status 70-100% - ANC = 1,000/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 8.0 g/dL - Serum creatinine = 2.0 times upper limit of normal (ULN) - Total serum bilirubin = 1.5 times ULN - AST and ALT = 2.5 times ULN (unless elevation is due to underlying malignancy) - Not pregnant or nursing - Negative pregnancy test by ultrasound - Fertile patients must use effective contraception - Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, follow-up tests for safety or effectiveness, and other study procedures - Mediport or Broviac access required for patients enrolled in part B of the study - No serious active infections - No significant (= grade 2) or persistent ongoing toxicity, including peripheral neuropathy, from prior therapy - None of the following within the past 6 months: - Myocardial infarction - Severe/unstable angina - Coronary/peripheral artery bypass graft - Symptomatic congestive heart failure - Cerebrovascular accident or transient ischemic attack - Pulmonary embolism - No contraindication to any of the study drugs - No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, interfere with the interpretation of study results, and, in the judgement of the investigator, may make the patient inappropriate for study entry - No concurrent anti-retroviral therapy for HIV-positive patients - Recovered from prior radiotherapy or surgery - Residual grade 1 toxicities allowed - No prior alvocidib - At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), immunotherapy, or radiotherapy - More than 4 weeks since prior major surgery - No other concurrent approved or investigational anticancer treatment, including surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or immunotherapy - No concurrent participation in another investigational treatment clinical trial - Concurrent participation in supportive care trials or non-treatment trials (e.g., quality of life or laboratory analysis studies) allowed - No concurrent vitamins, antioxidants, herbal preparations, or supplements, except for a single-tablet multivitamin |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Tower Cancer Research Foundation | Beverly Hills | California |
United States | University of Chicago Comprehensive Cancer Center | Chicago | Illinois |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
United States | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania |
United States | UPMC-Presbyterian Hospital | Pittsburgh | Pennsylvania |
United States | Mayo Clinic | Rochester | Minnesota |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Riverview Hospital | Wisconsin Rapids | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate defined as the ratio of the number of patients who achieve a CR or PR divided by the number of evaluable patients, as assessed by RECIST criteria | Evaluable patients are those patients who are able to complete at least one cycle of therapy or have progressed any time during therapy. | Within 3 courses of treatment | No |
Secondary | Progression-free survival | Summarized using the methods of Kaplan and Meier. | From treatment start until first documented progression or death, assessed up to 4 years | No |
Secondary | Time to tumor response | From treatment start until first documented CR or PR, assessed up to 4 years | No | |
Secondary | Toxicity, graded using the NCI CTCAE version 4.0 | Toxicities will be summarized by maximum grade per patient across all cycles, separately for each phase if applicable. | Up to 4 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00467051 -
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
|
Phase 2 | |
Completed |
NCT02283658 -
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
|
Phase 2 | |
Completed |
NCT01652794 -
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
|
Phase 1 | |
Withdrawn |
NCT01558778 -
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
|
N/A | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Completed |
NCT01079832 -
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00408681 -
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease After Donor Stem Cell Transplant
|
N/A | |
Completed |
NCT00228358 -
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
|
Phase 1 | |
Terminated |
NCT00042952 -
Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00897442 -
Collecting Tumor Samples From Patients With Gynecological Tumors
|
N/A | |
Terminated |
NCT01159067 -
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
|
Phase 2 | |
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
Suspended |
NCT02122185 -
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 2 |